Abstract: https://www.acpjournals.org/doi/10.7326/M23-2196
URL goes live when the embargo lifts
Earlier this summer, the Advisory Committee on Immunization Practices (ACIP) at the U.S. Centers for Disease Control and Prevention (CDC) voted in favor of a recommendation that adults 60 years and older receive a single dose of respiratory syncytial virus (RSV) vaccine, using shared clinical decision-making. Two new vaccines – RSVpreF (ABRYSVO) by Pfizer and RSVPreF3 (Arexvy) by GSK – are approved for use in this population and show robust protection against RSV. As several vaccines emerge offering protection to both the old and the very young, ACIP member Camille Nelson Kotton, MD, says this is an exciting time for RSV prevention.
In her commentary, Dr. Kotton shares key highlights from the vaccine trials including efficacy and safety data and offers insight into the discussion surrounding the shared decision-making recommendation. The editorial is published in Annals of Internal Medicine.
Media contacts: For an embargoed PDF, please contact Angela Collom at acollom@acponline.org. To speak with the corresponding author Camille Nelson Kotton, MD, please email Noah Brown at Nbrown9@mgb.org.
